In agreement with results described above, at day 10 after the transplant, there was no difference between the levels of TNF-α, IFN-γ, CCL2, CCL3 and CCL5 in the mice with experimental GVHD regardless of whether they received treatment with fullerol (data not shown). This evidence concerns the gene CCL3 and graft versus host disease.